FX-909

Phase 1Small molecule

FFlare Therapeutics Inc.

FX-909 is one of 5 small molecule programs targeting Advanced Urothelial Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Urothelial CarcinomaActive, not recruiting

Advanced Urothelial CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Advanced Urothelial Carcinoma

#DrugCompanyPhaseTrials

Zanzalintinib

Merck & Co.

Phase 2

1 2

Keytruda

Merck & Co.

Phase 1

1 3

Truqap

AstraZeneca

Preclinical

1 4

Halaven

Eisai

Preclinical

1 5

FX-909

FFlare Therapeutics Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Active, not recruiting

Advanced Urothelial Carcinoma

NCT05929235

Clinical

Trials by Indication[1]

Advanced Urothelial Carcinoma1 trial

A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 (as Monotherapy or in Combination With Pembrolizumab) in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Active, not recruiting·FFlare Therapeutics Inc.·Phase 1·NCT05929235·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FX-909. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FX-909 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FX-909. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Flare Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: FFlare Therapeutics Inc.

FX-909

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Advanced Urothelial Carcinoma1 trial

References

Drug Info

Quick Facts

Related News